The filing says Silo received software, technology and related intellectual property, but does not explain how they may help its business. The warrant could add shares later, but the filing does not show whether the assets will bring enough business value to balance that possibility.
The filing does not say how the assets fit Silo's business or what value they may bring. The seller can later use the warrant to buy up to 300,000 shares, starting in April 2027. The filing gives no basis to tell whether the assets' value balances the possible increase in shares.
Follow Silo Pharma, Inc. (SILO) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for SILO